Forbes: University Of Toronto, Canadian Biotech Company Collaborate On Cannabinoid-Based COVID-19 Treatment

06/23/2020

A Canadian biopharmaceutical company focused on cannabinoid-based products has been awarded a Mitacs grant (sponsored by the Canadian government) to work on a treatment for lung inflammation associated with COVID-19, in tandem with the University of Toronto’s faculty of pharmacy.

According to information procured exclusively, the publicly traded company in question, Avicanna Inc, will be announcing on Tuesday morning that it is expanding its research collaboration with Dr. Christine Allen's Research Group. This group, operating in the Leslie Dan Faculty of Pharmacy at the University of Toronto, will now be working on the “expedited development” of the aforementioned cannabinoid-based treatment for lung inflammation associated with COVID-19.

Read more...

 

 


Media Contact

Heather Young
Director, Communications
604-818-0020 | hyoung@mitacs.ca

Mitacs

ErinRose Handy
Manager, Communications
604-822-4476 | ehandy@mitacs.ca

Mitacs